Attempts to overcome this limitation have included the development of bispecific antibodies, such as TG-1801 and IMM0306, that target both CD47 and tumor cells, thereby aiming to restrict activity against non-tumor cells [35,36,37]. This evidence concerns the gene CD47 and neoplasm.